Reported Sunday, Monopar Presents Phase 3 Data At AAN 2026 Showing ALXN1840 Delivers Greater Neurologic Benefit And Lower Worsening Rates Versus Standard Of Care In Wilson Disease

Benzinga Newsdesk www.benzinga.com Positive 95.8%

Neg 0% Neu 0% Pos 95.8%

Comments

No comments yet. Be the first!